Generex Biotechnology Corporation (GNBT)

1.01
OTC Markets
Prev Close 1.05
Day Low/High 1.00 / 1.05
52 Wk Low/High 0.08 / 3.10
Exchange OTC Markets
Shares Outstanding 60.36B
Market Cap 63.37M
Div & Yield N.A. (N.A)

Latest News

Generex Biotechnology Announces Investor Conference Call Agenda Wednesday, January 16, At 4:00 P.m. Eastern

Generex Biotechnology Announces Investor Conference Call Agenda Wednesday, January 16, At 4:00 P.m. Eastern

Generex Biotechnology Corporation ( www.generex.

Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch Of FDA Cleared Excellagen® Wound Conforming Gel Matrix With Three Dosage Options

Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch Of FDA Cleared Excellagen® Wound Conforming Gel Matrix With Three Dosage Options

Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that Olaregen Therapeutix Inc.

Generex Biotechnology Announces Acquisition Of Surgical Supply And Distribution Company

Generex Biotechnology Announces Acquisition Of Surgical Supply And Distribution Company

Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has entered into a letter of intent (LOI) to acquire Medisource Partners, an FDA-registered distributor of medical and surgical products including bone grafts and...

Generex Biotechnology Announces Acquisition Of Surgical Device Manufacturer

Generex Biotechnology Announces Acquisition Of Surgical Device Manufacturer

Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has entered into a letter of intent (LOI) to acquire Pantheon Medical - Foot & Ankle, a manufacturer of specialty orthopedic surgery products and tools.

Generex Biotechnology Completes Acquisition Of Olaregen Therapeutix Inc.

Generex Biotechnology Completes Acquisition Of Olaregen Therapeutix Inc.

Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has completed the acquisition of 51% of Olaregen Therapeutix Inc.

Generex Biotechnology Announces The Launch Of A New Corporate Website

Generex Biotechnology Announces The Launch Of A New Corporate Website

Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has relaunched its corporate website to provide details on a revamped organizational structure, a talented and experienced management team, and a forward-looking vision...

Generex Biotechnology Completes Acquisition Of Regentys Corporation

Generex Biotechnology Completes Acquisition Of Regentys Corporation

Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has completed the acquisition of 51% of Regentys™ Corporation, a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal...

Generex Biotechnology CEO Joe Moscato Attending J.P. Morgan Healthcare Conference

Generex Biotechnology CEO Joe Moscato Attending J.P. Morgan Healthcare Conference

Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that Joe Moscato, the company's CEO is attending the annual J.

Generex Biotechnology Provides Update On NuGenerex Immuno-Oncology

Generex Biotechnology Provides Update On NuGenerex Immuno-Oncology

Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to provide an update on operational and strategic developments at NuGenerex Immuno-Oncology (previously Antigen Express), a wholly-owned subsidiary.

Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements For Excellagen® Wound Healing Collagen Matrix

Generex Biotechnology Partner Olaregen Therapeutix Inc. Signs Manufacturing Agreements For Excellagen® Wound Healing Collagen Matrix

Generex Biotechnology Corporation (OTCMKTS:GNBT) today announced that its partially, soon to be fully-owned subsidiary, Olaregen Therapeutix, Inc.

Generex Biotechnology Partner Olaregen Therapeutix Inc. Establishes Sales Force And Distribution Team For The Commercial Launch Of Excellagen

Generex Biotechnology Partner Olaregen Therapeutix Inc. Establishes Sales Force And Distribution Team For The Commercial Launch Of Excellagen

Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that their partially-owned, but soon to be wholly-owned subsidiary, Olaregen Therapeutix has established a premier sales force in the wound care space and contracted with a...

Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval For ECMH™ For Treatment Of Ulcerative Colitis

Generex Biotechnology Partner Regentys Corporation Receives European Patent Approval For ECMH™ For Treatment Of Ulcerative Colitis

Generex Biotechnology Corporation (OTCQB:GNBT) announced today that Regentys Corporation (formerly Asana Medical, Inc.

Generex Biotechnology Partner Olaregen Therapeutix Sponsors Annual Meeting Of Innovations In Wound Healing

Generex Biotechnology Partner Olaregen Therapeutix Sponsors Annual Meeting Of Innovations In Wound Healing

Generex Biotechnology Corporation (OTCQB:GNBT) announced today that Olaregen Therapeutix, a regenerative medicine company contracted to become a subsidiary of Generex, was a co-sponsor of the Annual Meeting of Innovations in Wound Healing (IWH) held...

Generex Biotechnology Receives IND Approval From FDA For Phase II Combination Study Using AE37 Plus Keytruda® (pembrolizumab) For The Treatment Of Triple Negative Breast Cancer

Generex Biotechnology Receives IND Approval From FDA For Phase II Combination Study Using AE37 Plus Keytruda® (pembrolizumab) For The Treatment Of Triple Negative Breast Cancer

Generex Biotechnology Corporation (OTCQB:GNBT) today announced that the FDA had reviewed the company's investigational new drug (IND) application and given notification that the study can proceed.

Generex Provides Stock Market Alert

Generex Provides Stock Market Alert

Generex Biotechnology Corporation ("Generex" or "Company") ( www.generex.

Generex Posts Slides, Script & Recording Of Investor Conference Call

Generex Posts Slides, Script & Recording Of Investor Conference Call

Generex Biotechnology Corporation ( www.generex.

Generex Biotechnology Expands Medical Device & Wound Care Portfolio With Acquisition Of Regentys Corporation

Generex Biotechnology Expands Medical Device & Wound Care Portfolio With Acquisition Of Regentys Corporation

Generex Biotechnology Corporation (OTCMKTS:GNBT) is pleased to announce that the company has signed a Binding Letter of Intent to acquire 51% of Regentys Corporation, a regenerative medicine company focused on developing treatments for patients with...

Generex Biotechnology Adds World-Class Leadership To Executive Management Team

Generex Biotechnology Adds World-Class Leadership To Executive Management Team

Generex Biotechnology Corporation (OTCMKTS:GNBT) announced today the appointment of Anthony J.

Generex Biotechnology Expands Medical Device Portfolio With Acquisition Of Olaregen Therapeutix Inc.

Generex Biotechnology Expands Medical Device Portfolio With Acquisition Of Olaregen Therapeutix Inc.

Generex Biotechnology Corporation (OTCMKTS:GNBT) announced today the signing of a Letter of Intent to acquire 51 percent of Olaregen Therapeutix Inc.

Generex Biotechnology Expands Medical Device Portfolio With Acquisition Of Olaregen Therapeutix Inc.

Generex Biotechnology Expands Medical Device Portfolio With Acquisition Of Olaregen Therapeutix Inc.

Announces Commercial Launch of FDA Approved Excellagen®, Proprietary, Patented Wound Care Product Focused on the Treatment of Complicated Wounds including Diabetic Ulcers and 16 Other FDA Approved Indications

Generex Biotechnology Signs Clinical Trial Agreement With The NSABP Foundation, Inc. For Phase II Clinical Trial Of AE37 In Combination With Pembrolizumab (Keytruda®) For Treatment Of Triple-Negative Breast Cancer

Generex Biotechnology Signs Clinical Trial Agreement With The NSABP Foundation, Inc. For Phase II Clinical Trial Of AE37 In Combination With Pembrolizumab (Keytruda®) For Treatment Of Triple-Negative Breast Cancer

Generex Biotechnology Corporation (OTCMKTS:GNBT) has signed a clinical trial agreement (CTA) with the NSABP Foundation, Inc.

Generex Provides Stock Market Alert

Generex Provides Stock Market Alert

Generex Biotechnology Corporation ( www.generex.

Generex Announces Investor Conference Call; Management To Provide Update On Initiatives & Strategic Plans

Generex Announces Investor Conference Call; Management To Provide Update On Initiatives & Strategic Plans

Generex Biotechnology Corporation ( www.generex.

Generex Announces Appointment Of Executive Management Team

Generex Announces Appointment Of Executive Management Team

Generex Biotechnology Corporation ( www.generex.

Generex Revises Record & Payment Dates For 20:1 Stock Dividend

Generex Revises Record & Payment Dates For 20:1 Stock Dividend

Generex Biotechnology Corporation ( www.generex.